Woodline Partners LP Has $6.42 Million Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

Woodline Partners LP boosted its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 5.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 485,073 shares of the biotechnology company's stock after buying an additional 25,094 shares during the quarter. Woodline Partners LP owned 1.59% of AnaptysBio worth $6,422,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its holdings in AnaptysBio by 131.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 1,531 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in AnaptysBio in the 4th quarter valued at $40,000. AlphaQuest LLC increased its stake in AnaptysBio by 1,891.5% in the 4th quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after buying an additional 4,237 shares during the period. Virtus ETF Advisers LLC increased its stake in AnaptysBio by 24.7% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock valued at $63,000 after buying an additional 936 shares during the period. Finally, Russell Investments Group Ltd. increased its stake in AnaptysBio by 1,585.8% in the 4th quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock valued at $75,000 after buying an additional 5,360 shares during the period.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ANAB. Wolfe Research initiated coverage on shares of AnaptysBio in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 price objective on the stock. Wells Fargo & Company boosted their target price on shares of AnaptysBio from $40.00 to $51.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. HC Wainwright reissued a "neutral" rating and set a $22.00 target price on shares of AnaptysBio in a research report on Tuesday, March 4th. Johnson Rice restated a "buy" rating on shares of AnaptysBio in a report on Wednesday, March 26th. Finally, JPMorgan Chase & Co. increased their target price on AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $35.88.

AnaptysBio Trading Down 1.5%

NASDAQ:ANAB traded down $0.31 during mid-day trading on Tuesday, reaching $20.13. 566,607 shares of the stock were exchanged, compared to its average volume of 602,126. AnaptysBio, Inc. has a 1-year low of $12.21 and a 1-year high of $41.31. The firm has a market capitalization of $591.42 million, a PE ratio of -3.31 and a beta of -0.20. The business has a fifty day moving average price of $19.44 and a 200 day moving average price of $18.23.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, beating analysts' consensus estimates of ($1.30) by $0.02. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $27.77 million during the quarter, compared to analyst estimates of $15.27 million. On average, sell-side analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio announced that its Board of Directors has approved a share buyback program on Monday, March 24th that allows the company to buyback $75.00 million in shares. This buyback authorization allows the biotechnology company to purchase up to 13.1% of its stock through open market purchases. Stock buyback programs are often a sign that the company's management believes its stock is undervalued.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.